PHARMADRUG ADVANCES PRODUCT AND CLINICAL DEVELOPMENT OF CEPHARANTHINE TO TREAT RARE CANCERS AND INFECTIOUS...
PHARMADRUG INITIATES DMT RESEARCH ACTIVITIES VIA COLLABORATION WITH THE UNIVERSITY OF MICHIGAN FOR FOUNDATIONAL DMT...
PHARMADRUG FILES FOR FDA ORPHAN DRUG DESIGNATION FOR DMT IN KIDNEY TRANSPLANTATION AND EXPANDS ON ITS PSYCHEDELICS STRATEGY Toronto...
PHARMADRUG FILES FOR FDA ORPHAN DRUG DESIGNATION FOR DMT IN STROKE Toronto, Ontario--(Newsfile Corp. - February 11, 2021) - PharmaDrug Inc. (CSE:...
PHARMADRUG APPOINTS WORLD-RENOWNED DMT EXPERT DR. STEVEN A. BARKER TO ITS SCIENTIFIC ADVISORY BOARD FOR PSYCHEDELIC...
PHARMADRUG SIGNS SUPPLY AGREEMENT WITH GLOBAL CANNABIS SUPPLIER AND Provides update on german operations and balance sheet improvements...
PHARMADRUG COMPLETES ACQUISITION OF SAIRIYO THERAPEUTICS INC. Toronto, Ontario -- February 2, 2021 -- InvestorsHub...
PHARMADRUG ENTERS DEFINITIVE AGREEMENT FOR ACQUISITION OF SAIRIYO THERAPEUTICS INC. WHO RECENTLY RECEIVED ORPHAN DRUG DESIGNATION FROM FDA FOR...
PHARMADRUG ANNOUNCES LOI TO ACQUIRE SAIRIYO THERAPEUTICS INC. Toronto, Ontario -- January 12, 2021 -- InvestorsHub...
TORONTO, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ, OTCQB:LMLLF...
TORONTO, June 14, 2019 (GLOBE NEWSWIRE) -- Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased...
TORONTO, June 07, 2019 (GLOBE NEWSWIRE) -- Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) wishes to...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.